<DOC>
	<DOCNO>NCT00001015</DOCNO>
	<brief_summary>To determine maximum long-term dosage ribavirin ( RBV ) safe free serious side effect patient AIDS AIDS related illness . Also , determine effect different dosage level biologic marker efficacy , amount AIDS virus ( HIV ) number T cell patient 's blood . RBV new drug capable inhibit growth AIDS virus laboratory little effect normal human cell . In early test RBV AIDS patient , drug well tolerate safe , favorable result suggest RBV extensively study patient AIDS advance AIDS relate complex ( ARC ) .</brief_summary>
	<brief_title>A Study Ribavirin Treatment Patients With AIDS AIDS-Related Problems</brief_title>
	<detailed_description>RBV new drug capable inhibit growth AIDS virus laboratory little effect normal human cell . In early test RBV AIDS patient , drug well tolerate safe , favorable result suggest RBV extensively study patient AIDS advance AIDS relate complex ( ARC ) . Patients select three patient group : - Patients AIDS , take zidovudine ( AZT ) within 30 day entry study discontinue AZT intolerance . - Patients AIDS relate disease take AZT within 30 day entry study , discontinue AZT intolerance . - Patients AIDS AIDS relate disease AZT intolerance require cessation therapy . This outpatient study ; patient see weekly first 4 week , every week week 12 , every 4 week duration 24 week treatment portion study . Patients three diagnostic group enrol dose level . For first 3 day entry study , patient receive low dose RBV every 6 hour . Subsequent dosage increase maximum tolerated dose ( MTD ) reach . The MTD group define dose 4 8 patient group develop toxicity require change discontinuation dosage . Patients experience significant toxicity may continue study low dose determine long-term tolerance .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Shortcourse therapy ( 7 day ) oral acyclovir . Shortcourse therapy ( 7 day ) ketoconazole . Topical medication . Aerosolized pentamidine prophylactic purpose . Concurrent Treatment : Allowed : Blood transfusion hemoglobin toxicity . Patients must two positive HIV p24 antigen test titer = &gt; 70 picograms least 72 hour apart within 1 month prior entry , last must within 2 week start therapy . Prior Medication : Allowed : Zidovudine ( AZT ) , without cessation therapy require due intolerance . AZT therapy must discontinue least 30 day prior study entry . Exclusion Criteria Coexisting Condition : Patients follow exclude : Active opportunistic infection , symptomatic visceral Kaposi 's sarcoma ( KS ) progression KS within month prior entry study , neoplasms KS , basal cell carcinoma skin , situ carcinoma cervix . Significant diarrhea , define = &gt; 3 liquid stool per day within past week . Concurrent Medication : Excluded : Ongoing systemic therapy and/or prophylaxis AIDSdefining opportunistic infection . Antineoplastic therapy . Other experimental medication . Systemic chemoprophylaxis Pneumocystis carinii pneumonia . Chronic ( &gt; 7 day ) oral acyclovir therapy . Concurrent Treatment : Excluded : Blood transfusion unless = &gt; grade 3 hemoglobin toxicity . Patients follow exclude : Active opportunistic infection , symptomatic visceral Kaposi 's sarcoma ( KS ) progression KS within month prior entry study , neoplasms KS , basal cell carcinoma skin , situ carcinoma cervix . Significant diarrhea , define = &gt; 3 liquid stool per day within past week . Prior Medication : Excluded within 30 day study entry : Antiretroviral agent include zidovudine ( AZT ) . Biologic modifier . Systemic corticosteroid . Prior Treatment : Excluded within 2 month study entry : Blood transfusion except take zidovudine ( AZT ) may receive transfusion within previous month . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Ribavirin</keyword>
	<keyword>T-Lymphocytes</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>